P021
Alzheimer's Disease
PreclinicalActive
Key Facts
About Phanes Biotech
Phanes Biotech is an early-stage biotech company targeting the massive and growing unmet medical need in Alzheimer's disease. The company is advancing a dual-platform strategy, with its lead candidate, P021, a small molecule designed to promote neuroregeneration, and PB43D, a tau immunotherapy aimed at a key pathological hallmark of the disease. Founded and led by a team with deep neuroscience expertise, including renowned Alzheimer's researcher Dr. Khalid Iqbal, the company is positioned in the high-risk, high-reward space of disease-modifying Alzheimer's therapies, operating in a fiercely competitive landscape dominated by large pharmaceutical companies.
View full company profileTherapeutic Areas
Other Alzheimer's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| NUZ-001 | Neurizon Therapeutics | Preclinical |
| ALZN002 | Alzamend Neuro | Preclinical |
| PB43D | Phanes Biotech | Preclinical |
| UB-311 | Vaxxinity | Phase 2 |
| Lecanemab | BioArctic | Launched |
| BAN2401 | BioArctic | Preclinical |
| Undisclosed Programs | johnson-and-johnson-innovative-medicine | Pipeline |
| MK-6240 (florquinitau) | Lantheus Medical Imaging | Regulatory Filing |
| NAV-4694 (flutafuranol) | Lantheus Medical Imaging | Phase 3 |
| LNTH-2620/PI-2620 | Lantheus Medical Imaging | Phase 3 |
| itMSCs | Stemedica Cell Technologies | Clinical Development |
| Alzheimer's program | Risen Pharma Tech | Clinical (China & US) |